Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Brunswick, DJ; Amsterdam, JD; Fawcett, J; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Beasley, CM
   Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy
   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
   
   D.J. Brunswick et al., "Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy", J CL PSYCH, 21(6), 2001, pp. 616-618
2. Czekalla, J; Beasley, CM; Dellva, MA; Berg, PH; Grundy, S
   Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis
   JOURNAL OF CLINICAL PSYCHIATRY
   
   J. Czekalla et al., "Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis", J CLIN PSY, 62(3), 2001, pp. 191-198
3. Czekalla, J; Kollack-Walker, S; Beasley, CM
   Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics
   JOURNAL OF CLINICAL PSYCHIATRY
   
   J. Czekalla et al., "Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics", J CLIN PSY, 62, 2001, pp. 35-40
4. McGrath, PJ; Stewart, JW; Petkova, E; Quitkin, FM; Amsterdam, JD; Fawcett, J; Reimherr, FW; Rosenbaum, JF; Beasley, CM
   Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression
   JOURNAL OF CLINICAL PSYCHIATRY
   
   P.J. McGrath et al., "Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression", J CLIN PSY, 61(7), 2000, pp. 518-524
5. Beasley, CM; Nilsson, ME; Koke, SC; Gonzales, JS
   Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: A meta-analysis of the 20-mg/day dose
   JOURNAL OF CLINICAL PSYCHIATRY
   
   C.M. Beasley et al., "Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: A meta-analysis of the 20-mg/day dose", J CLIN PSY, 61(10), 2000, pp. 722-728
6. Beasley, CM; Koke, SC; Nilsson, ME; Gonzales, JS
   Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis
   CLINICAL THERAPEUTICS
   
   C.M. Beasley et al., "Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis", CLIN THER, 22(11), 2000, pp. 1319
7. Revicki, DA; Genduso, LA; Hamilton, SH; Ganoczy, D; Beasley, CM
   Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial
   QUALITY OF LIFE RESEARCH
   
   D.A. Revicki et al., "Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial", QUAL LIFE R, 8(5), 1999, pp. 417-426
8. Hudson, MF; Beasley, CM; Benedict, RH; Carlson, JR; Craig, BF; Mason, SC
   Elder abuse - Some African American views
   JOURNAL OF INTERPERSONAL VIOLENCE
   
   M.F. Hudson et al., "Elder abuse - Some African American views", J INTERP V, 14(9), 1999, pp. 915-939
9. Callaghan, JT; Bergstrom, RF; Ptak, LR; Beasley, CM
   Olanzapine - Pharmacokinetic and pharmacodynamic profile
   CLINICAL PHARMACOKINETICS
   
   J.T. Callaghan et al., "Olanzapine - Pharmacokinetic and pharmacodynamic profile", CLIN PHARMA, 37(3), 1999, pp. 177-193
10. Perry, PJ; Sanger, T; Beasley, CM
    Plasma olanzapine and clinical response: Reply
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    
    P.J. Perry et al., "Plasma olanzapine and clinical response: Reply", J CL PSYCH, 19(2), 1999, pp. 193-194
11. Zajecka, J; Amsterdam, JD; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Tamura, RN; Sundell, KL; Michelson, D; Beasley, CM
    Changes in adverse events reported by patients during 6 months of fluoxetine therapy
    JOURNAL OF CLINICAL PSYCHIATRY
    
    J. Zajecka et al., "Changes in adverse events reported by patients during 6 months of fluoxetine therapy", J CLIN PSY, 60(6), 1999, pp. 389-394
12. Beasley, CM
    Olanzapine and tardive dyskinesia - Author's reply
    BRITISH JOURNAL OF PSYCHIATRY
    
    C.M. Beasley, "Olanzapine and tardive dyskinesia - Author's reply", BR J PSYCHI, 175, 1999, pp. 392-392
13. Tran, PV; Tollefson, GD; Sanger, TM; Lu, YL; Berg, PH; Beasley, CM
    Olanzapine versus haloperidol in the treatment of schizoaffective disorder- Acute and long-term therapy
    BRITISH JOURNAL OF PSYCHIATRY
    
    P.V. Tran et al., "Olanzapine versus haloperidol in the treatment of schizoaffective disorder- Acute and long-term therapy", BR J PSYCHI, 174, 1999, pp. 15-22
14. Beasley, CM; Dellva, MA; Tamura, RN; Morgenstern, H; Glazer, WM; Ferguson, K; Tollefson, GD
    Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol
    BRITISH JOURNAL OF PSYCHIATRY
    
    C.M. Beasley et al., "Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol", BR J PSYCHI, 174, 1999, pp. 23-30
15. Beasley, CM
    Response to letter of Professor Tim Lambert
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
    
    C.M. Beasley, "Response to letter of Professor Tim Lambert", AUST NZ J P, 33(1), 1999, pp. 121-122
16. Michelson, D; Amsterdam, JD; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Zajecka, J; Sundell, KL; Kim, Y; Beasley, CM
    Changes in weight during a 1-year trial of fluoxetine
    AMERICAN JOURNAL OF PSYCHIATRY
    
    D. Michelson et al., "Changes in weight during a 1-year trial of fluoxetine", AM J PSYCHI, 156(8), 1999, pp. 1170-1176
17. BEASLEY CM
    SUICIDALITY WITH FLUOXETINE
    CNS DRUGS
    
    C.M. Beasley, "SUICIDALITY WITH FLUOXETINE", CNS DRUGS, 9(6), 1998, pp. 513-514
18. BEASLEY CM; SAYLER ME; KIESLER GM; POTVIN JH; SANGER TM; TOLLEFSON GD
    THE INFLUENCE OF PHARMACOTHERAPY ON SELF-DIRECTED AND EXTERNALLY-DIRECTED AGGRESSION IN SCHIZOPHRENIA
    Schizophrenia research
    
    C.M. Beasley et al., "THE INFLUENCE OF PHARMACOTHERAPY ON SELF-DIRECTED AND EXTERNALLY-DIRECTED AGGRESSION IN SCHIZOPHRENIA", Schizophrenia research, 29(1-2), 1998, pp. 28-28
19. REAMS SG; SANGER TM; BEASLEY CM
    OLANZAPINE IN THE TREATMENT OF ELDERLY PATIENTS WITH SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS
    Schizophrenia research
    
    S.G. Reams et al., "OLANZAPINE IN THE TREATMENT OF ELDERLY PATIENTS WITH SCHIZOPHRENIA AND RELATED PSYCHOTIC DISORDERS", Schizophrenia research, 29(1-2), 1998, pp. 151-152
20. TAMURA RN; BEASLEY CM; DELLVA MA; GLAZER WM; MORGENSTERN H; TOLLEFSON GD
    WHAT IS THE DIFFERENTIAL RISK OF TARDIVE-DYSKINESIA WITH THE NOVEL ANTIPSYCHOTIC OLANZAPINE
    Schizophrenia research
    
    R.N. Tamura et al., "WHAT IS THE DIFFERENTIAL RISK OF TARDIVE-DYSKINESIA WITH THE NOVEL ANTIPSYCHOTIC OLANZAPINE", Schizophrenia research, 29(1-2), 1998, pp. 176-176
21. JONES B; CRAWFORD AMK; BEASLEY CM; TOLLEFSON GD
    THE ACUTE AND LONG-TERM EFFECT OF OLANZAPINE COMPARED WITH PLACEBO AND HALOPERIDOL ON SERUM PROLACTIN CONCENTRATION
    Schizophrenia research
    
    B. Jones et al., "THE ACUTE AND LONG-TERM EFFECT OF OLANZAPINE COMPARED WITH PLACEBO AND HALOPERIDOL ON SERUM PROLACTIN CONCENTRATION", Schizophrenia research, 29(1-2), 1998, pp. 204-205
22. WRIGHT P; TOLLEFSON GD; BEASLEY CM; TAMURA RN; TRAN PV; POTVIN JII
    A BLINDED, CONTROLLED, LONG-TERM STUDY OF THE COMPARATIVE INCIDENCE OF TREATMENT - EMERGENT TARDIVE-DYSKINESIA WITH OLANZAPINE OR HALOPERIDOL
    Schizophrenia research
    
    P. Wright et al., "A BLINDED, CONTROLLED, LONG-TERM STUDY OF THE COMPARATIVE INCIDENCE OF TREATMENT - EMERGENT TARDIVE-DYSKINESIA WITH OLANZAPINE OR HALOPERIDOL", Schizophrenia research, 29(1-2), 1998, pp. 206-206
23. HAMILTON SH; REVICKI DA; GENDUSO LA; BEASLEY CM
    OLANZAPINE VERSUS PLACEBO AND HALOPERIDOL - QUALITY-OF-LIFE AND EFFICACY RESULTS OF THE NORTH-AMERICAN DOUBLE-BLIND TRIAL
    Neuropsychopharmacology
    
    S.H. Hamilton et al., "OLANZAPINE VERSUS PLACEBO AND HALOPERIDOL - QUALITY-OF-LIFE AND EFFICACY RESULTS OF THE NORTH-AMERICAN DOUBLE-BLIND TRIAL", Neuropsychopharmacology, 18(1), 1998, pp. 41-49
24. HUDSON MF; ARMACHAIN WD; BEASLEY CM; CARLSON JR
    ELDER ABUSE - 2 NATIVE-AMERICAN VIEWS
    The Gerontologist
    
    M.F. Hudson et al., "ELDER ABUSE - 2 NATIVE-AMERICAN VIEWS", The Gerontologist, 38(5), 1998, pp. 538-548
25. TRAN PV; DELLVA MA; TOLLEFSON GD; WENTLEY AL; BEASLEY CM
    ORAL OLANZAPINE VERSUS ORAL HALOPERIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA AND RELATED PSYCHOSES
    British Journal of Psychiatry
    
    P.V. Tran et al., "ORAL OLANZAPINE VERSUS ORAL HALOPERIDOL IN THE MAINTENANCE TREATMENT OF SCHIZOPHRENIA AND RELATED PSYCHOSES", British Journal of Psychiatry, 172, 1998, pp. 499-505
26. TOLLEFSON GD; SANGER TM; BEASLEY CM; TRAN PV
    A DOUBLE-BLIND, CONTROLLED COMPARISON OF THE NOVEL ANTIPSYCHOTIC OLANZAPINE VERSUS HALOPERIDOL OR PLACEBO ON ANXIOUS AND DEPRESSIVE SYMPTOMS ACCOMPANYING SCHIZOPHRENIA
    Biological psychiatry
    
    G.D. Tollefson et al., "A DOUBLE-BLIND, CONTROLLED COMPARISON OF THE NOVEL ANTIPSYCHOTIC OLANZAPINE VERSUS HALOPERIDOL OR PLACEBO ON ANXIOUS AND DEPRESSIVE SYMPTOMS ACCOMPANYING SCHIZOPHRENIA", Biological psychiatry, 43(11), 1998, pp. 803-810
27. MICHELSON D; TAMURA R; SUNDELL K; BEASLEY CM
    EARLY AND LATE ADVERSE EVENT PROFILES ASSOCIATED WITH FLUOXETINE TREATMENT
    Biological psychiatry
    
    D. Michelson et al., "EARLY AND LATE ADVERSE EVENT PROFILES ASSOCIATED WITH FLUOXETINE TREATMENT", Biological psychiatry, 43, 1998, pp. 301-301
28. REIMHERR FW; AMSTERDAM JD; QUITKIN FM; ROSENBAUM JF; FAVA M; ZAJECKA J; BEASLEY CM; MICHELSON D; ROBACK P; SUNDELL K
    OPTIMAL LENGTH OF CONTINUATION THERAPY IN DEPRESSION - A PROSPECTIVE ASSESSMENT DURING LONG-TERM FLUOXETINE TREATMENT
    The American journal of psychiatry
    
    F.W. Reimherr et al., "OPTIMAL LENGTH OF CONTINUATION THERAPY IN DEPRESSION - A PROSPECTIVE ASSESSMENT DURING LONG-TERM FLUOXETINE TREATMENT", The American journal of psychiatry, 155(9), 1998, pp. 1247-1253
29. AMSTERDAM JD; FAWCETT J; QUITKIN FM; REIMHERR FW; ROSENBAUM JF; MICHELSON D; BEASLEY CM
    FLUOXETINE AND NORFLUOXETINE - DR. AMSTERDAM AND COLLEAGUES REPLY
    The American journal of psychiatry
    
    J.D. Amsterdam et al., "FLUOXETINE AND NORFLUOXETINE - DR. AMSTERDAM AND COLLEAGUES REPLY", The American journal of psychiatry, 155(11), 1998, pp. 1637-1637
30. TOLLEFSON GD; BEASLEY CM; KUNTZ AJ
    OLANZAPINE ON TRIAL - REPLY
    The American journal of psychiatry
    
    G.D. Tollefson et al., "OLANZAPINE ON TRIAL - REPLY", The American journal of psychiatry, 155(1), 1998, pp. 153-155
31. DELLVA MA; TRAN P; TOLLEFSON GD; WENTLEY AL; BEASLEY CM
    STANDARD OLANZAPINE VERSUS PLACEBO AND INEFFECTIVE DOSE OLANZAPINE INTHE MAINTENANCE TREATMENT OF SCHIZOPHRENIA
    Psychiatric services
    
    M.A. Dellva et al., "STANDARD OLANZAPINE VERSUS PLACEBO AND INEFFECTIVE DOSE OLANZAPINE INTHE MAINTENANCE TREATMENT OF SCHIZOPHRENIA", Psychiatric services, 48(12), 1997, pp. 1571-1577
32. BEASLEY CM; HAMILTON SH; CRAWFORD AM; DELLVA MA; TOLLEFSON GD; TRAN PV; BLIN O; BEUZEN JN
    OLANZAPINE VERSUS HALOPERIDOL - ACUTE-PHASE RESULTS OF THE INTERNATIONAL DOUBLE-BLIND OLANZAPINE TRIAL
    European neuropsychopharmacology
    
    C.M. Beasley et al., "OLANZAPINE VERSUS HALOPERIDOL - ACUTE-PHASE RESULTS OF THE INTERNATIONAL DOUBLE-BLIND OLANZAPINE TRIAL", European neuropsychopharmacology, 7(2), 1997, pp. 125-137
33. CRAWFORD AMK; BEASLEY CM; TOLLEFSON GD
    THE ACUTE AND LONG-TERM EFFECT OF OLANZAPINE COMPARED WITH PLACEBO AND HALOPERIDOL ON SERUM PROLACTIN CONCENTRATIONS
    Schizophrenia research
    
    A.M.K. Crawford et al., "THE ACUTE AND LONG-TERM EFFECT OF OLANZAPINE COMPARED WITH PLACEBO AND HALOPERIDOL ON SERUM PROLACTIN CONCENTRATIONS", Schizophrenia research, 26(1), 1997, pp. 41-54
34. TOLLEFSON GD; LU YL; SANGER TM; BEASLEY CM; TRAN PV
    OLANZAPINE IN THE TREATMENT OF SCHIZOAFFECTIVE DISORDER
    Schizophrenia research
    
    G.D. Tollefson et al., "OLANZAPINE IN THE TREATMENT OF SCHIZOAFFECTIVE DISORDER", Schizophrenia research, 24(1-2), 1997, pp. 192-193
35. TOLLEFSON GD; SANGER TM; BEASLEY CM
    THE COURSE OF PRIMARY AND SECONDARY NEGATIVE SYMPTOMS IN A CONTROLLEDTRIAL WITH OLANZAPINE
    Schizophrenia research
    
    G.D. Tollefson et al., "THE COURSE OF PRIMARY AND SECONDARY NEGATIVE SYMPTOMS IN A CONTROLLEDTRIAL WITH OLANZAPINE", Schizophrenia research, 24(1-2), 1997, pp. 192-192
36. BEASLEY CM
    UNTITLED - RESPONSE
    Neuropsychopharmacology
    
    C.M. Beasley, "UNTITLED - RESPONSE", Neuropsychopharmacology, 16(1), 1997, pp. 89-90
37. TRAN PV; DELLVA MA; TOLLEFSON GD; BEASLEY CM; POTVIN JH; KIESLER GM
    EXTRAPYRAMIDAL SYMPTOMS AND TOLERABILITY OF OLANZAPINE VERSUS HALOPERIDOL IN THE ACUTE TREATMENT OF SCHIZOPHRENIA
    The Journal of clinical psychiatry
    
    P.V. Tran et al., "EXTRAPYRAMIDAL SYMPTOMS AND TOLERABILITY OF OLANZAPINE VERSUS HALOPERIDOL IN THE ACUTE TREATMENT OF SCHIZOPHRENIA", The Journal of clinical psychiatry, 58(5), 1997, pp. 205-211
38. BEASLEY CM; TOLLEFSON GD; TRAN PV
    EFFICACY OF OLANZAPINE - AN OVERVIEW OF PIVOTAL CLINICAL-TRIALS
    The Journal of clinical psychiatry
    
    C.M. Beasley et al., "EFFICACY OF OLANZAPINE - AN OVERVIEW OF PIVOTAL CLINICAL-TRIALS", The Journal of clinical psychiatry, 58, 1997, pp. 7-12
39. BEASLEY CM; TOLLEFSON GD; TRAN PV
    SAFETY OF OLANZAPINE
    The Journal of clinical psychiatry
    
    C.M. Beasley et al., "SAFETY OF OLANZAPINE", The Journal of clinical psychiatry, 58, 1997, pp. 13-17
40. BLUMENFIELD M; LEVY NB; SPINOWITZ B; CHARYTAN C; BEASLEY CM; DUBEY AK; SOLOMON RJ; TODD R; GOODMAN A; BERGSTROM RF
    FLUOXETINE IN DEPRESSED-PATIENTS ON DIALYSIS
    International journal of psychiatry in medicine
    
    M. Blumenfield et al., "FLUOXETINE IN DEPRESSED-PATIENTS ON DIALYSIS", International journal of psychiatry in medicine, 27(1), 1997, pp. 71-80
41. TOLLEFSON GD; BEASLEY CM; TAMURA RN; TRAN PV; POTVIN JH
    BLIND, CONTROLLED, LONG-TERM STUDY OF THE COMPARATIVE INCIDENCE OF TREATMENT-EMERGENT TARDIVE-DYSKINESIA WITH OLANZAPINE OR HALOPERIDOL
    The American journal of psychiatry
    
    G.D. Tollefson et al., "BLIND, CONTROLLED, LONG-TERM STUDY OF THE COMPARATIVE INCIDENCE OF TREATMENT-EMERGENT TARDIVE-DYSKINESIA WITH OLANZAPINE OR HALOPERIDOL", The American journal of psychiatry, 154(9), 1997, pp. 1248-1254
42. AMSTERDAM JD; FAWCETT J; QUITKIN FM; REIMHERR FW; ROSENBAUM JF; MICHELSON D; HORNIGROHAN M; BEASLEY CM
    FLUOXETINE AND NORFLUOXETINE PLASMA-CONCENTRATIONS IN MAJOR DEPRESSION - A MULTICENTER STUDY
    The American journal of psychiatry
    
    J.D. Amsterdam et al., "FLUOXETINE AND NORFLUOXETINE PLASMA-CONCENTRATIONS IN MAJOR DEPRESSION - A MULTICENTER STUDY", The American journal of psychiatry, 154(7), 1997, pp. 963-969
43. TOLLEFSON GD; BEASLEY CM; TRAN PV; STREET JS; KRUEGER JA; TAMURA RN; GRAFFEO KA; THIEME ME
    OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE AND SCHIZOPHRENIFORM DISORDERS - RESULTS OF AN INTERNATIONAL COLLABORATIVE TRIAL
    The American journal of psychiatry
    
    G.D. Tollefson et al., "OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE AND SCHIZOPHRENIFORM DISORDERS - RESULTS OF AN INTERNATIONAL COLLABORATIVE TRIAL", The American journal of psychiatry, 154(4), 1997, pp. 457-465
44. TOLLEFSON GD; BEASLEY CM; TRAN PV; TAMURA RN; SANGER TM; WOOD A; BEUZEN JN
    OLANZAPINE VERSUS HALOPERIDOL - RESULTS OF THE MULTICENTER INTERNATIONAL TRIAL
    Schizophrenia research
    
    G.D. Tollefson et al., "OLANZAPINE VERSUS HALOPERIDOL - RESULTS OF THE MULTICENTER INTERNATIONAL TRIAL", Schizophrenia research, 18(2-3), 1996, pp. 3-3
45. BEASLEY CM; TOLLEFSON G; TRAN P; SATTERLEE W; SANGER T; HAMILTON S; FABRE L; SMALL J; ERESHEFSKY L; TRUE J; NEMEROFF C; RISCH SC; PERRY PJ; POTKIN SG; BORISON RL; JAMES S; MELTZER HY; IQBAL N; FANN WE; GEWIRTZ GR; LANDBLOOM R; ROYBYRNE PP; TUASON VB; CARMAN JS; STOKES PE; WILLIAMS R; ANCILL RJ; MACEWAN GW; GUJAVARTY KS; JONES B; LOHR JB
    OLANZAPINE VERSUS PLACEBO AND HALOPERIDOL - ACUTE-PHASE RESULTS OF THE NORTH-AMERICAN DOUBLE-BLIND OLANZAPINE TRIAL
    Neuropsychopharmacology
    
    C.M. Beasley et al., "OLANZAPINE VERSUS PLACEBO AND HALOPERIDOL - ACUTE-PHASE RESULTS OF THE NORTH-AMERICAN DOUBLE-BLIND OLANZAPINE TRIAL", Neuropsychopharmacology, 14(2), 1996, pp. 111-123
46. LEVY NB; BLUMENFIELD M; BEASLEY CM; DUBEY AK; SOLOMON RJ; TODD R; GOODMAN A; BERGSTROM RR
    FLUOXETINE IN DEPRESSED-PATIENTS WITH RENAL-FAILURE AND IN DEPRESSED-PATIENTS WITH NORMAL KIDNEY-FUNCTION
    General hospital psychiatry
    
    N.B. Levy et al., "FLUOXETINE IN DEPRESSED-PATIENTS WITH RENAL-FAILURE AND IN DEPRESSED-PATIENTS WITH NORMAL KIDNEY-FUNCTION", General hospital psychiatry, 18(1), 1996, pp. 8-13
47. LEVY NB; BLUMENFIELD M; BEASLEY CM; DUBEY AK; SOLOMON RJ; TODD R; GOODMAN A; BERGSTROM RF
    FLUOXETINE IS SAFE AND EFFICACIOUS IN DEPRESSED HEMODIALYSIS-PATIENTS
    Psychosomatics
    
    N.B. Levy et al., "FLUOXETINE IS SAFE AND EFFICACIOUS IN DEPRESSED HEMODIALYSIS-PATIENTS", Psychosomatics, 37(2), 1996, pp. 211-211
48. BEASLEY CM; SANGER T; SATTERLEE W; TOLLEFSON G; TRAN P; HAMILTON S; GREEN A; DOTT S; PFISTER G; ROXAS L; SMALL J; THOMAS M; AMES D; SCHOOLER N; BAKER R; LEVINE R; FABRE L; FRIEDEL R; SAFFERMAN A; LIEBERMAN J; STAHL S
    OLANZAPINE VERSUS PLACEBO - RESULTS OF A DOUBLE-BLIND, FIXED-DOSE OLANZAPINE TRIAL
    Psychopharmacology
    
    C.M. Beasley et al., "OLANZAPINE VERSUS PLACEBO - RESULTS OF A DOUBLE-BLIND, FIXED-DOSE OLANZAPINE TRIAL", Psychopharmacology, 124(1-2), 1996, pp. 159-167
49. TRAN PV; BEASLEY CM; TOLLEFSON GD; BEUZEN JN; HOLMAN SL; SANGER TM; SATTERLEE WG
    OLANZAPINE - A PROMISING ATYPICAL ANTIPSYCHOTIC AGENT
    Schizophrenia research
    
    P.V. Tran et al., "OLANZAPINE - A PROMISING ATYPICAL ANTIPSYCHOTIC AGENT", Schizophrenia research, 15(1-2), 1995, pp. 169-169
50. GOLDSTEIN DJ; HAMILTON SH; MASICA DN; BEASLEY CM
    FLUOXETINE IN DEPRESSED GERIATRIC-PATIENTS - EFFECT ON WEIGHT
    Clinical pharmacology and therapeutics
    
    D.J. Goldstein et al., "FLUOXETINE IN DEPRESSED GERIATRIC-PATIENTS - EFFECT ON WEIGHT", Clinical pharmacology and therapeutics, 57(2), 1995, pp. 201-201
51. AMSTERDAM JD; HORNIGROHAN M; ROSENBAUM JF; QUITKIN FM; FAWCETTE J; REIMHERR FW; BEASLEY CM
    FLUOXETINE AND NORFLUOXETINE PLASMA-LEVELS IN MAJOR DEPRESSION
    Biological psychiatry
    
    J.D. Amsterdam et al., "FLUOXETINE AND NORFLUOXETINE PLASMA-LEVELS IN MAJOR DEPRESSION", Biological psychiatry, 37(9), 1995, pp. 606-606
52. HARRISON DA; SATTERLEE W; TRAN P; BEASLEY CM; TOLLEFSON GD
    OLANZAPINE - A POTENTIAL ATYPICAL ANTIPSYCHOTIC AGENT - PHASE-II CLINICAL FINDINGS
    Schizophrenia research
    
    D.A. Harrison et al., "OLANZAPINE - A POTENTIAL ATYPICAL ANTIPSYCHOTIC AGENT - PHASE-II CLINICAL FINDINGS", Schizophrenia research, 11(2), 1994, pp. 107-107
53. TOLLEFSON GD; RAMPEY AH; BEASLEY CM; ENAS GG; POTVIN JH
    ABSENCE OF A RELATIONSHIP BETWEEN ADVERSE EVENTS AND SUICIDALITY DURING PHARMACOTHERAPY FOR DEPRESSION
    Journal of clinical psychopharmacology
    
    G.D. Tollefson et al., "ABSENCE OF A RELATIONSHIP BETWEEN ADVERSE EVENTS AND SUICIDALITY DURING PHARMACOTHERAPY FOR DEPRESSION", Journal of clinical psychopharmacology, 14(3), 1994, pp. 163-169
54. BEASLEY CM
    FLUOXETINE-DOPAMINERGIC INTERACTION DATA
    The Journal of clinical psychiatry
    
    C.M. Beasley, "FLUOXETINE-DOPAMINERGIC INTERACTION DATA", The Journal of clinical psychiatry, 55(2), 1994, pp. 77-78
55. TOLLEFSON GD; BEASLEY CM; TRAN PV; SANGER T
    OLANZAPINE - A NOVEL ANTIPSYCHOTIC WITH A BROAD-SPECTRUM PROFILE
    Biological psychiatry
    
    G.D. Tollefson et al., "OLANZAPINE - A NOVEL ANTIPSYCHOTIC WITH A BROAD-SPECTRUM PROFILE", Biological psychiatry, 35(9), 1994, pp. 746-747
56. BEASLEY CM; MASICA DN; HEILIGENSTEIN JH; WHEADON DE; ZERBE RL
    POSSIBLE MONOAMINE-OXIDASE INHIBITOR SEROTONIN UPTAKE INHIBITOR INTERACTION - FLUOXETINE CLINICAL-DATA AND PRECLINICAL FINDINGS
    Journal of clinical psychopharmacology
    
    C.M. Beasley et al., "POSSIBLE MONOAMINE-OXIDASE INHIBITOR SEROTONIN UPTAKE INHIBITOR INTERACTION - FLUOXETINE CLINICAL-DATA AND PRECLINICAL FINDINGS", Journal of clinical psychopharmacology, 13(5), 1993, pp. 312-320
57. BERGSTROM RF; BEASLEY CM; LEVY NB; BLUMENFIELD M; LEMBERGER L
    THE EFFECTS OF RENAL AND HEPATIC-DISEASE ON THE PHARMACOKINETICS, RENAL TOLERANCE, AND RISK-BENEFIT PROFILE OF FLUOXETINE
    International clinical psychopharmacology
    
    R.F. Bergstrom et al., "THE EFFECTS OF RENAL AND HEPATIC-DISEASE ON THE PHARMACOKINETICS, RENAL TOLERANCE, AND RISK-BENEFIT PROFILE OF FLUOXETINE", International clinical psychopharmacology, 8(4), 1993, pp. 261-266
58. BEASLEY CM; POTVIN JH
    FLUOXETINE - ACTIVATING AND SEDATING EFFECTS
    International clinical psychopharmacology
    
    C.M. Beasley e J.H. Potvin, "FLUOXETINE - ACTIVATING AND SEDATING EFFECTS", International clinical psychopharmacology, 8(4), 1993, pp. 271-275
59. HEILIGENSTEIN JH; BEASLEY CM; POTVIN JH
    FLUOXETINE NOT ASSOCIATED WITH INCREASED AGGRESSION IN CONTROLLED CLINICAL-TRIALS
    International clinical psychopharmacology
    
    J.H. Heiligenstein et al., "FLUOXETINE NOT ASSOCIATED WITH INCREASED AGGRESSION IN CONTROLLED CLINICAL-TRIALS", International clinical psychopharmacology, 8(4), 1993, pp. 277-280
60. BEASLEY CM; SAYLER ME; POTVIN JH
    FLUOXETINE VERSUS AMITRIPTYLINE IN THE TREATMENT OF MAJOR DEPRESSION - A MULTICENTER TRIAL
    International clinical psychopharmacology
    
    C.M. Beasley et al., "FLUOXETINE VERSUS AMITRIPTYLINE IN THE TREATMENT OF MAJOR DEPRESSION - A MULTICENTER TRIAL", International clinical psychopharmacology, 8(3), 1993, pp. 143-149
61. GOLDSTEIN DJ; RAMPEY AH; POTVIN JH; MASICA DN; BEASLEY CM
    ANALYSES OF SUICIDALITY IN DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS OFPHARMACOTHERAPY FOR WEIGHT-REDUCTION
    The Journal of clinical psychiatry
    
    D.J. Goldstein et al., "ANALYSES OF SUICIDALITY IN DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS OFPHARMACOTHERAPY FOR WEIGHT-REDUCTION", The Journal of clinical psychiatry, 54(8), 1993, pp. 309-316